Eisenmenger Syndrome: Recent Advances in Pharmacotherapy

Author(s): Sarmad Said, Mateo Porres-Aguilar, Mateo Porres-Munoz, Debabrata Mukherjee

Journal Name: Cardiovascular & Hematological Agents in Medicinal Chemistry
(Formerly Current Medicinal Chemistry - Cardiovascular & Hematological Agents)

Volume 11 , Issue 4 , 2013

Become EABM
Become Reviewer


Over the last decade advanced therapies for the management of pulmonary arterial hypertension have been introduced. These agents have also been effective in reducing pulmonary vascular resistance in patients with Eisenmenger syndrome. Specific guidelines focusing on modern therapies for Eisenmenger syndrome however do not exist to date. More recently, clinical trials in patients with Eisenmenger syndrome demonstrated a significant clinical improvement with favorable safety and tolerability profile. This review aims to summarize newly reported pharmacological agents used in patients with Eisenmenger syndrome.

Keywords: Congenital heart disease, endothelin receptor antagonists, eisenmenger syndrome, phosphodiesterase type-5 inhibitors, prostanoids, pulmonary arterial hypertension.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2013
Page: [289 - 296]
Pages: 8
DOI: 10.2174/1871525712666140321095519
Price: $65

Article Metrics

PDF: 80